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1. Introduction
Endometriosis is characterized by the presence of endometrial-like functional 
tissue located outside the uterine cavity, most commonly in the pelvic peritoneum, 
ovaries and rectovaginal septum, and more rarely in the pericardium, pleura and 
central nervous system. The studies indicate a prevalence of up to 20% of women of 
reproductive age [1] and 30–50% of infertile women with endometriosis [1].
2. Clinical condition
The clinical condition of the patient with endometriosis is quite variable. The 
patient may be asymptomatic, refer only to infertility, or have symptoms such as 
severe dysmenorrhea, profound dyspareunia, chronic pelvic pain, ovulatory pain, 
urinary symptoms or peri-menstrual bowel movements, and chronic fatigue. 
Gynecological examination may be normal, but the presence of pain in uterine 
mobilization, uterine retroversion, or increase in ovarian volume is suggestive of 
endometriosis, although it is not specific. Other conditions, such as irritable bowel 
syndrome, pelvic inflammatory disease, and interstitial cystitis may present similar 
symptoms and should be included in the differential diagnosis. Signs suggestive 
of deep infiltrative endometriosis are palpable nodulations in the posterior vaginal 
fornix or rectovaginal septum, thickening of the uterosacral ligaments, or viola-
ceous lesions in the vagina [2].
3. Diagnostic evaluation of endometriosis
Although the definitive diagnosis of endometriosis requires surgical interven-
tion, preferably through videolaparoscopy, several findings in physical, imaging, 
and laboratory tests can already predict, with a high degree of reliability, that 
the patient has endometriosis. To date, no biochemical marker can be considered 
as an endometriosis endpoint, but Ca-125, when collected on the first or second 
day of the menstrual cycle, may be useful for the diagnosis of advanced stage 
endometriosis when the values are higher than 100 IU/mL [3]. Although normal 
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concentrations do not exclude the disease, cases with elevated preoperative levels 
may aid in patient follow-up and clinical suspicion of recurrence of endometriosis. 
More recently, some cytokines have been studied as new nonsurgical endometriosis 
markers. Interleukin-6 (IL-6) appears to perform better than other cytokines in 
discriminating patients with endometriosis [4]. The first imaging test to be applied 
to the patient with a history and physical examination suggestive of endometriosis 
is transvaginal pelvic ultrasound, preferably with intestinal preparation. A study 
by Abrão et al. [5], evaluating the accuracy of this test, demonstrated a sensitivity 
of 94% and a specificity of 98% in the identification of foci of deep endometriosis. 
If the test is normal, the patient may not have endometriosis or have noninfiltrative 
initial disease. On the other hand, if the test is conclusive for ovarian endometriosis, 
rectovaginal septum or rectosigmoid, or urinary tract, treatment may be indicated 
without additional imaging tests. For evaluation of endometriomas larger than 
2 cm, transvaginal ultrasonography is an efficient method, according to Moore 
et al. [6]. The presence of ovarian masses with a doubtful diagnostic hypothesis 
can be better evaluated with magnetic resonance imaging (MRI). Changes sug-
gestive of rectovaginal septum disease, uterosacral, or rectosigmoid ligaments 
may be confirmed by rectal echoendoscopy or MRI. Rectal echoendoscopy allows 
the identification of the distance between the lesion and the rectal lumen as well 
as extrinsic compressions and submucosal lesions of the rectum [7]. MRI also 
allows the identification of deep disease with invasion of the intestinal tract, but 
it does not make it possible to specify the intestinal layer affected by the lesion 
[8]. Transvaginal ultrasonography for the diagnosis of bladder endometriosis has 
been reported as an effective method, with sensitivity of 71.4% and specificity of 
100% [9]. Ultrasonography suggestive of bladder or ureteral endometriosis can 
be complemented with excretory urography, which may show ureteral narrowing. 
Uro-resonance can be used as an alternative method to excretory urography for 
evaluation of renal collecting system dilatations. Although the available imaging 
exams presented good accuracy in the diagnosis of endometriosis, laparoscopy 
with lesion biopsy for anatomopathological analysis is still the gold standard in the 
diagnosis of endometriosis.
4. Classification of endometriosis
After videolaparoscopy, endometriosis can be classified according to the 
histological type of the implants, with the anatomical location of the disease—
peritoneum, ovary or rectum—or by the extension of the disease to the pelvic 
organs. The most commonly used classification is that of the American Society of 
Reproductive Medicine—revised in 1996 [10]. This classification rates minimal, 
mild, moderate, or severe endometriosis due to the extent of disease in the perito-
neum and ovaries, as well as the presence of tube-ovarian and Douglas sack bottom 
block. This classification, although with some limitations, is quite useful in the 
orientation of postsurgical treatment, especially when the patient’s complaint is 
infertility.
5. Critical analysis of treatments for endometriosis
The therapeutic approach to endometriosis varies, depending on the patient’s 
complaint, pelvic pain or infertility, although such complaints are often associated. 
Gonadotropin-releasing hormone (GnRH) analogues, GnRHa, may be indicated 
for three months and then continue with oral contraceptives. If the patient has 
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recurrence of pain, or an image suggestive of endometrioma greater than 3 cm or 
suspected of adherence, surgery should be indicated.
6. Surgical treatment of endometriosis
Surgical treatment of endometriosis involves procedures of low complexity, such 
as the treatment of superficial foci and the release of tendon adhesions, to complex 
interventions in the ovaries, Douglas sacs, intestines, bladder, and ureters, requir-
ing, in some cases, a multidisciplinary team. For several years, the surgical treat-
ment of endometriosis was based on the oncological principles of radical removal of 
the lesions. This principle is still used when it comes to cases of intestinal or ureteral 
stenosis or ovarian masses of doubtful characteristics. However, we currently know 
that there is no correlation between the disease with the severity of the symptoms, 
as well as the reproductive prognosis and long-term recurrence of pain [11]. In 
addition, many patients present infertility associated with pain, requiring that the 
surgical procedure be conservative. Based on these considerations, some authors 
recommend surgical treatment only for patients who do not respond to drug treat-
ment, as well as for those who wish to become pregnant spontaneously [12]. There 
are few published randomized clinical trials evaluating the outcome of surgical 
treatment of symptomatic endometriosis. A review by Vercellini et al. [12] describes 
symptomatic improvement after conservative treatment of around 60–80%, with 
recurrence of symptoms and reoperation rate ranging from 12 to 58% between 
studies.
For the patient with infertility, follicle ablation and adhesiolysis appear to 
improve fertility in the minimal and mild degrees of disease [1]. In cases of mod-
erate or severe degrees, there are no randomized clinical trials or meta-analyses 
available to answer if resection of foci would increase gestation rates.
7. Molecular genetics and endometriosis
Endometriosis exhibits similarity with cancer since endometrial cell implants 
require neovascularization to establish, grow, and invade tissues. In addition, the 
etiopathogenic theories of endometriosis involve growth factors and cytokines 
associated with regulation of cell multiplication and neoangiogenesis that may act 
on carcinogenesis. It is estimated that 1% of cases of endometriosis is related to 
cancer, and for some types of endometriosis, its benign nature has been question-
able [13, 14].
Although the definitive diagnosis of endometriosis necessitates a surgical inter-
vention, called video-laparoscopy, several findings in the physical, imaging and 
laboratory examinations can already predict, with a high degree of reliability, that 
the patient has this disease. During this surgical procedure, it is possible to visualize 
lesions suggestive of the disease and to obtain a tissue specimen for anatomopatho-
logical analysis and confirmation of the diagnosis of endometriosis [15]. The clas-
sification used for endometriosis is that of the American Society of Reproductive 
Medicine (ASRM), revised in 1996, which rates this disease in minimal (stage I), 
mild (stage II), moderate (stage III), or severe (stage IV) [16]. Currently, the most 
common treatments are surgery, ovarian suppression therapy, or the association of 
both [13, 15].
The cause of endometriosis remains unknown. However, there is evidence of 
immunological [17, 18], environmental [19], and genetic [18, 20] factors involved in 
its pathogenesis.
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Regarding the immune response, the role of cytokines in the development of 
endometriosis [21–23] is highlighted, and elevated levels of several of them have 
been found in patients with endometriosis [23, 25]. The same group of investiga-
tors [24, 26] evaluated the levels of cytokines involved in the Th1 immune response 
patterns (interleukin (IL)-2, tumor necrosis factor (TNF)-alpha and interferon 
(IFN) and Th2 (IL-4 and IL-10) in patients with endometriosis (n = 65) and in 
those without the disease (n = 33). Podgaec et al. [24] observed elevation in IFN-
gamma and IL-10 levels in patients with endometriosis, evidencing the coexistence 
of both responses. However, when considering the ratio of cytokine levels to these 
responses, IL-4 and IL-10 predominated, thus reflecting a possible shift to the 
Th2 immune response component. In the subsequent study, 18 cytokine levels 
were associated with the clinical symptoms of endometriosis. Patients with endo-
metriosis who had depth dyspareunia and infertility exhibited elevated levels of 
TNF-alpha and IL-2, respectively. These cytokines are related to the Th1 immune 
response, and almost 70% of the patients who presented these results exhibited 
deep endometriosis. The authors conclude that when specific clinical data are asso-
ciated with elevated production of certain cytokines, there is a Th1 response pattern 
that may be associated with deep endometriosis. Induction of Th1 immune response 
was also reported by Fairbanks et al. [25], who showed elevated levels of IL-12 in 
patients with severe endometriosis.
The contribution of environmental factors to the development of endometrio-
sis was reviewed by Bellelis et al. [19] who related their influence and diet to the 
genetics of this disease. They concluded that the mechanism by which dioxin and its 
similes (2,3,7,8-tetrachlorodibenzo-p-dioxin/TCDD and polychlorinated biphenyls/
PCBs) act to alter endometrial physiology is uncertain and speculative. They also 
state that there is insufficient evidence regarding the use of diets as preventive fac-
tors or even adjuvants in the treatment of endometriosis.
The genetic and hereditary basis of endometriosis was evidenced in the study 
by Bellelis et al. [19] in which approximately 5.3% of the patients reported a first-
degree family history with a history of endometriosis. Familial aggregation, a high 
concordance rate in monozygotic twins, and a 4–7% risk for first-degree relatives 
support a contribution of genetic factors to the pathogenesis of this disease [14]. 
In this context, the identification of genetic variants or single nucleotide polymor-
phisms (SNPs), responsible for susceptibility to endometriosis, has been the subject 
of investigation in recent years [26–28]. Different classifications were proposed for 
endometriosis candidate genes.
8. Conclusions
What are the objectives of the genetic study of individuals? There is a great 
interest of the medical community and also much concern of the lay press about 
the potential benefits and harms of genetic screening, gene therapy, and even the 
possibility of cloning individuals. The current use of genetic tests for the detection 
and treatment of endometriosis is still at an early stage, but very important. The 
determination of susceptibility markers will be increasingly explored in clinical 
studies, and their uses will be much more defined.
Still, it seems increasingly likely that major changes will occur over the next 
decade in how we evaluate and treat our patients. In particular, surgeons and clini-
cians will have the opportunity to use a number of new tests to predict the future 
appearance of endometriosis in patients still free of the disease. They may have the 
power to explore the best therapeutic modality for a particular patient according to 
their genetic makeup. And they will be able to more specifically target prevention 
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measures for family members of people already affected by the disease. It should be 
understood that molecular diagnosis, especially in asymptomatic individuals, does 
not mean disease, but an increased risk of developing this disease. Ethical implica-
tions exist and should not be underestimated. Patients should be advised about the 
likely implications of such tests not only after, but especially before the achievement 
of these.
A major step has already been overcome and we currently have basic tools for a 
new leap in understanding human pathologies responsible for much of the world’s 
mortality. Bridging the great barrier that still separates this basic knowledge from 
clinical practice is still a much greater challenge.
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